Lipid‐lowering therapy of everolimus‐related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET)

Hypertriglyceridaemia (HTG) is a potentially serious side effect of everolimus therapy. We here report a case of severe HTG in an everolimus‐treated patient and provide recommendations for its management.

[1]  K. Kotulska,et al.  Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening , 2015, Anti-cancer drugs.

[2]  A. Armstrong,et al.  A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. , 2014, Clinical genitourinary cancer.

[3]  T. Choueiri,et al.  Metabolic complications with the use of mTOR inhibitors for cancer therapy. , 2014, Cancer treatment reviews.

[4]  D. Franz.  Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex , 2013, Biologics : targets & therapy.

[5]  Hyo Song Kim,et al.  Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma , 2013, Cancer Chemotherapy and Pharmacology.

[6]  J. Dancey,et al.  Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[8]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[9]  R. Pearson.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2011 .

[10]  E. Baudin,et al.  Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[12]  H. Katus,et al.  Beneficial Effect of Omega-3 Fatty Acids on Sirolimus- or Everolimus-Induced Hypertriglyceridemia in Heart Transplant Recipients , 2008, Transplantation.

[13]  Suzanne F. Jones,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Falconi,et al.  Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. , 2005, Endocrine-related cancer.

[15]  P. Nambi,et al.  Sirolimus upregulates aP2 expression in human monocytes and macrophages. , 2004, Transplantation proceedings.

[16]  C. Ballantyne,et al.  Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients DOI 10.1194/jlr.M100392-JLR200 , 2002, Journal of Lipid Research.

[17]  C. Ballantyne,et al.  Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. , 2001, Transplantation.

[18]  J. Cristol,et al.  Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. , 2000, Transplantation proceedings.

[19]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.